Novo Nordisk A/S (NYSE:NVO) Shares Purchased by Asio Capital LLC

Asio Capital LLC raised its holdings in Novo Nordisk A/S (NYSE:NVO) by 5.3% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 5,301 shares of the company’s stock after purchasing an additional 266 shares during the period. Asio Capital LLC’s holdings in Novo Nordisk A/S were worth $456,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in NVO. Xponance Inc. grew its holdings in Novo Nordisk A/S by 27.6% during the 2nd quarter. Xponance Inc. now owns 2,665 shares of the company’s stock worth $380,000 after acquiring an additional 576 shares in the last quarter. AQR Capital Management LLC lifted its position in shares of Novo Nordisk A/S by 110.5% during the second quarter. AQR Capital Management LLC now owns 17,164 shares of the company’s stock worth $2,450,000 after purchasing an additional 9,012 shares during the last quarter. Daymark Wealth Partners LLC grew its stake in Novo Nordisk A/S by 15.9% in the second quarter. Daymark Wealth Partners LLC now owns 6,290 shares of the company’s stock worth $898,000 after purchasing an additional 864 shares in the last quarter. Maverick Capital Ltd. increased its holdings in Novo Nordisk A/S by 272.9% in the second quarter. Maverick Capital Ltd. now owns 7,849 shares of the company’s stock valued at $1,120,000 after buying an additional 5,744 shares during the last quarter. Finally, The Manufacturers Life Insurance Company increased its holdings in Novo Nordisk A/S by 2.2% in the second quarter. The Manufacturers Life Insurance Company now owns 131,876 shares of the company’s stock valued at $18,824,000 after buying an additional 2,817 shares during the last quarter. 11.54% of the stock is currently owned by hedge funds and other institutional investors.

Novo Nordisk A/S Stock Up 8.4 %

NVO stock opened at $87.94 on Friday. Novo Nordisk A/S has a fifty-two week low of $78.17 and a fifty-two week high of $148.15. The company has a quick ratio of 0.75, a current ratio of 0.94 and a debt-to-equity ratio of 0.43. The stock has a market cap of $394.65 billion, a PE ratio of 28.46, a price-to-earnings-growth ratio of 0.90 and a beta of 0.45. The firm’s 50-day simple moving average is $95.35 and its 200 day simple moving average is $115.17.

Analysts Set New Price Targets

NVO has been the subject of a number of research analyst reports. Sanford C. Bernstein upgraded Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a report on Monday, January 6th. Cantor Fitzgerald reissued an “overweight” rating and set a $160.00 target price on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. BMO Capital Markets reduced their price target on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a research report on Monday, December 23rd. UBS Group upgraded shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research note on Wednesday, January 8th. Finally, StockNews.com downgraded Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research note on Sunday, December 29th. One research analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $145.25.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.